ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ABDX Abingdon Health Plc

7.60
-0.15 (-1.94%)
04 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Abingdon Health Plc ABDX London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.15 -1.94% 7.60 16:35:12
Open Price Low Price High Price Close Price Previous Close
7.75 7.70 8.20 7.60 7.75
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Abingdon Health ABDX Dividends History

No dividends issued between 04 Mar 2014 and 04 Mar 2024

Top Dividend Posts

Top Posts
Posted at 14/10/2023 13:42 by timbo003
Register for the seminar mentioned in the previous post (which includes a presentation from ABDX) here:
Posted at 14/10/2023 10:45 by sharesoc
ShareSoc is holding its first hybrid event in London on 19th Oct. Hear from Abingdon Health (ABDX) and other healthcare companies like Tristel Plc (TSTL), Inspiration Healthcare Group (IHC), Creo Medical Group (CREO) and GENincode (GENI). Attend in-person or online.📍 7760; Register: [...]
Posted at 11/4/2023 09:13 by mrmark1
In production now and launching in May with a big advertising campaign. Amazon and other sites/stores with co-branded products. ABDX is the exclusive sole manufacturer and distributor for the worlds first saliva pregnancy test for the UK.
Posted at 07/10/2022 13:02 by bandflex
The settlement agreement is in full and final settlement of the outstanding debt of GBP8.9m (excluding interest) and comprises:

i) A contractually required cash payment of GBP6.3m from DHSC to Abingdon, which is required to be paid to the Company on or before 22 July 2022; GBP1.5m of this cash payment will be held under charge until the outcome of the judicial review is known; and...

They received the £6.3m on 7/7/22, only £1.5m outstanding. That is their only interest in the case.
Posted at 01/8/2022 12:53 by blackhorse23
Don't see any further in here so switched to high growth stocks MCL ( LSE) .... 5p to 20p many times last 6 month ... dividend yield & profitability is good ..
Posted at 06/4/2022 12:24 by bobdown2
A very large sell followed by 2 small buys and the share price is in the top half of the spread. I suggest you look at todays trades to see how a sellers position unwinds.
I need 12 pence to be in profit.i have made four trades in three or four days. And today the markets found out that abdx is still working with avacta.
A payment from the DHSC could double the share price at these levels. But I think they are drawing the process out to lower the settlement. Still contracts look to be arriving and abdx look to have come through the mess.
Posted at 05/4/2022 07:20 by tomboyb
Abingdon Health plc

("Abingdon" or "the Company")



Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test

Tests manufactured by Abingdon now authorised for sale



York, U.K. 5 April 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces it has successfully completed the technical transfer of the Vatic KnowNowᵀ test (Spike Test in USA) on behalf of its customer, leading diagnostics technology innovator Vatic Health Limited ("Vatic"), on schedule. This follows the conclusion of the scale-up and manufacture of three independent production-scale batches and Vatic has now approved the sale of tests manufactured by Abingdon. Abingdon has received initial purchase orders from Vatic for commercial sale, and manufacturing for these orders will now commence.



The Vatic KnowNowᵀ test is an easy-to-use saliva COVID-19 antigen test, which is the only test that identifies the virus by mimicking the surface of a human cell. This means the test only identifies "live" or "active" copies of the virus which are capable of cell entry and thereby infecting a human cell. Other tests, such as PCR and lateral flow antigen tests, can pick up harmless viral fragments with the potential for users to test positive once they are no longer infectious. Furthermore, the unique detection mechanism of the KnowNowᵀ test has been purposefully designed to be more robust to mutation than traditional antigen tests, making it more future-proofed for ongoing COVID-19 testing. Vatic have previously announced that this test detects variants of the SARS-CoV-2 virus including the Omicron variant.



The test is CE marked for professional use and has been submitted by Vatic to the US FDA for Emergency Use Approval (EUA).



Alex Sheppard, CEO of Vatic Health Limited, commented:

"We are excited to have concluded the transfer of our product to manufacture with Abingdon and to commence sales of our product. Our proprietary technology allows ease of use via a saliva specimen and only detects active virus -enabling individuals to know their infectivity status."



Dr Mona K. Omir, CTO of Vatic Health Limited, commented:

"Completing the Technical Transfer of the KnowNow test is a huge milestone in the Vatic Health journey and our ongoing collaboration with Abingdon Health. To bring such novel assay technology into routine manufacturing could be a true step change in diagnostics and we are excited for what this could mean for COVID-19 testing around the world."



Chris Yates, CEO of Abingdon Health plc, commented:

"We are delighted to have concluded this technical transfer and to begin manufacture of the product for Vatic at our Yorkshire facilities. This is an important addition to the COVID-19 testing toolbox and we look forward to continuing to work with Vatic as we manufacture the product to fulfil their requirements."
Posted at 02/4/2022 09:26 by 74tom
Always starts to pique my interest when a shorter appears to have a ‘god’ complex…

We saw a major short squeeze here last August from 27-85p and saw a number of smaller pops up to the long term downtrend line along the way.

The mid March bounce to 16p took ABDX clear of the downtrend resistance that had been in place since Dec 2020, which like it or not is a bullish sign.

Some other points;

- No, they didn’t wait as long as possible to release their final results, they have until 30th June (6 months post year end) - many examples of companies yet to report - SNG, AVCT being two off the top of my head.

- Yesterdays £50m ONT settlement shows DHSC were waiting until the new budget year to settle the disputes, so there is now a real prospect of getting the £8.4m + 8% interest on the overdue amounts…

- You seem to think this is priced in, I’d argue that 99% of day traders will have forgotten this exists and last remember it being in the 30/40/50p range so will pile in on the news, similar to recent 100/200% moves we’ve seen in AVCT & GDR, and cause a major spike. Also a stock that has had a short squeeze once is far more likely to have a second, especially from a lower level (traders that did well then will look to repeat the trick…)

The place to short would then be the top of said spike… being short now is just asking for a margin call.
Posted at 15/3/2022 09:23 by ramnik007
Perhaps Avacta and Abdx have found a way to produce Affimer based, and more accurate LFT. Interesting both rising in synch!
Posted at 15/2/2022 14:57 by shallow pockets
Don't hold your breath, Inv. This stock is just not bouncing from its lows. Why would it? Heavy on overhead. Heavy on capex. Starving of both product and income. No investors waiting outside the front door. And Omega's firesale of one of its factories probably values ABDX assets at as little as half of the current value. "Cheap" (based on previous over valuation due to the pandemic) can get cheaper because it wasn't cheap in the first place. Just over valued.

Target is 8p. Stay short. Sell bounces. No good news on the horizon.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com